Surgery for Lung Disease: Lobectomy, VATS, and Lung Volume Reduction

Surgical intervention for lung disease spans a spectrum from minimally invasive video-assisted procedures to open resections, each matched to specific anatomical and physiological conditions. This page covers the three most clinically significant categories — lobectomy, video-assisted thoracoscopic surgery (VATS), and lung volume reduction surgery (LVRS) — including how each works, when it applies, and the boundaries that govern patient selection. Understanding these procedures within the broader landscape of pulmonary medicine helps contextualize where surgery fits alongside medical and rehabilitative management.

Definition and Scope

Thoracic surgery for lung disease encompasses procedures that remove, reshape, or functionally decompress lung tissue to improve gas exchange, eliminate malignancy, or reduce mechanical hyperinflation. The three principal categories addressed here differ in approach, indication, and invasiveness:

Lobectomy: Surgical removal of one of the lung's anatomical lobes — 3 in the right lung, 2 in the left. This is the standard-of-care resection for early-stage non-small cell lung cancer (NSCLC), as defined in National Comprehensive Cancer Network (NCCN) guidelines for Stage I and Stage II disease.
Video-Assisted Thoracoscopic Surgery (VATS): A minimally invasive platform that uses a thoracoscope and 2–4 small port incisions (typically under 3 cm each) instead of a full thoracotomy. VATS can perform lobectomies, wedge resections, biopsies, and pleural procedures.
Lung Volume Reduction Surgery (LVRS): Resection of approximately 20–30% of the most hyperinflated, non-functional lung tissue in patients with severe emphysema, allowing the remaining lung and diaphragm to function more efficiently.

The regulatory context for pulmonary practice shapes how these procedures are approved, reimbursed, and credentialed at the institutional level. The Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination (NCD 240.1) specifically governing LVRS reimbursement, requiring that patients meet criteria established by the National Emphysema Treatment Trial (NETT).

How It Works

Lobectomy via Open Thoracotomy

Traditional open lobectomy involves a posterolateral thoracotomy incision, spreading of the ribs, and individual ligation of the lobar bronchus and pulmonary vessels before lobe removal. A chest drain is placed postoperatively, typically for 2–5 days. The procedure requires single-lung ventilation managed by anesthesia using a double-lumen endotracheal tube.

VATS Lobectomy

VATS lobectomy replicates the anatomical dissection of open lobectomy through thoracoscopic ports. A 2017 meta-analysis published in the Journal of Thoracic and Cardiovascular Surgery identified shorter hospital stays (averaging 4–5 days vs. 6–7 days for open surgery), lower rates of prolonged air leak, and reduced perioperative morbidity with VATS compared to open thoracotomy, though operative time can be longer in complex cases.

Robotic-assisted thoracoscopic surgery (RATS) is a further refinement, using a robotic platform — such as the da Vinci Surgical System — to enhance dexterity within the chest cavity. The American Association for Thoracic Surgery (AATS) recognizes RATS as equivalent in oncologic outcomes to VATS lobectomy in appropriately selected patients.

Lung Volume Reduction Surgery

LVRS targets upper-lobe-predominant emphysema with poor exercise capacity. The NETT, a randomized controlled trial involving 1,218 patients funded by the National Heart, Lung, and Blood Institute (NHLBI), demonstrated that LVRS improved survival and exercise capacity in patients with upper-lobe-predominant emphysema and low post-rehabilitation exercise capacity. Patients with FEV₁ below 20% predicted or diffuse (non-upper-lobe) emphysema showed higher 90-day mortality without survival benefit, a finding that now forms a hard exclusion criterion.

Bronchoscopic Lung Volume Reduction (BLVR)

As a less invasive alternative to surgical LVRS, endobronchial valve placement collapses hyperinflated lobes without resection. The FDA cleared the Zephyr Endobronchial Valve (Pulmonx) in 2018 for patients with heterogeneous emphysema and intact interlobar fissures. Relevant procedural context is covered under bronchoscopic interventions.

Common Scenarios

Surgical lung procedures are indicated across four broad clinical contexts:

Early-stage lung cancer: Lobectomy — open or VATS — is the preferred resection for Stage I–II NSCLC when pulmonary function permits. The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database tracks outcomes for over 100,000 annual thoracic procedures in the US.
Diagnostic tissue acquisition: VATS wedge resection obtains larger specimens than bronchoscopy for diffuse parenchymal lung diseases such as pulmonary fibrosis, where transbronchial biopsy yield is insufficient.
Severe emphysema with hyperinflation: LVRS or BLVR applies when medical management and pulmonary rehabilitation have been exhausted and the patient meets NETT physiological criteria.
Infectious or structural disease: Lobectomy addresses destroyed lung segments from chronic bronchiectasis, mycobacterial infection, or large lung abscesses unresponsive to antibiotics.

Decision Boundaries

Patient selection for thoracic surgery rests on three intersecting assessments:

Pulmonary Function Thresholds

The American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines recommend that preoperative predicted postoperative FEV₁ (ppoFEV₁) and predicted postoperative diffusing capacity for carbon monoxide (ppoDLCO) each exceed 40% predicted before proceeding with anatomic resection. Values between 30–40% warrant formal cardiopulmonary exercise testing (CPET), where a peak VO₂ above 15 mL/kg/min is generally considered an acceptable surgical risk threshold.

Oncologic Stage and Margin

For lung cancer, the decision between lobectomy and sublobar resection (segmentectomy or wedge) depends on tumor size and location. The CALGB 140503 trial (Alliance), published in The New England Journal of Medicine in 2023, demonstrated non-inferiority of sublobar resection for peripheral tumors ≤2 cm, which has begun shifting guidelines toward limited resection in this subgroup.

LVRS-Specific Exclusions

The NETT defined absolute exclusion criteria including: FEV₁ ≤20% predicted with either homogeneous emphysema or DLCO ≤20% predicted (the "high-risk" subgroup), active smoking within 4 months, clinically significant bronchiectasis, or a prior thoracic surgery. CMS NCD 240.1 ties Medicare reimbursement to documentation that these criteria were evaluated at an approved LVRS center.

VATS vs. Open Thoracotomy

The primary contraindications to VATS include dense pleural adhesions from prior surgery or infection, centrally located tumors requiring pneumonectomy, and prior ipsilateral chest radiation. In these cases, open thoracotomy remains the appropriate platform despite higher short-term morbidity.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)